Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Atossa Therapeutics, Inc. (ATOS)
USD2.44
+0.18 (+7.96%)
US NASDAQ Healthcare Biotechnology
Address
107 Spring Street 98104
Seattle, WA, US
Seattle, WA, US
CEO
Steven C. Quay
Website
atossatherapeutics.com
IPO
2012-11-08
CIK 1488039 ISIN US04962H7044
Description
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.44
+0.18 (+7.96%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
136.5K
Beta
1.15
Float Shares
8.61M
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.18% | -4.80% | -2.82% | +22.86% | -57.14% | -41.69% | -61.35% | -51.55% | -85.42% | -99.26% | -99.96% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
2.44
Low
10.00
+309.8%
Consensus
10.00
+309.8%
Median
10.00
+309.8%
High
10.00
+309.8%
DCF (Unlevered)
4.34
+78.0%
DCF (Levered)
4.80
+96.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
10.00
+309.8%
|
| Last Year | 1 |
10.00
+309.8%
|
| All Time | 2 |
42.50
+1,641.8%
|
Quality scores
Altman Z-Score
-8.35
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-34.7% Q1'26: -42.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +3,204.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.6% ★ Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
1.8K
est: 6.30M (-100.0%)
|
—
|
—
|
54.46M
54.46M – 54.46M
|
82.35M
82.35M – 82.35M
+51.2% YoY
|
122.03M
120.38M – 123.68M
+48.2% YoY
|
187.91M
187.91M – 187.91M
+54.0% YoY
|
301.56M
301.56M – 301.56M
+60.5% YoY
|
| EBITDA |
-12.49M
|
-27.60M
|
-37.13M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-12.76M
|
-27.62M
|
-37.14M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-15.76M
est: -11.10B (+99.9%)
|
-25.50M
est: -26.65M (+4.3%)
|
-34.77M
est: -33.60M (-3.5%)
|
-32.52M
-33.76M – -31.27M
+3.2% YoY
|
-18.65M
-32.74M – -4.56M
+42.6% YoY
|
22.64M
-3.51M – 48.37M
+221.4% YoY
|
35.69M
35.69M – 35.69M
+57.7% YoY
|
58.77M
58.77M – 58.77M
+64.7% YoY
|
| SGA |
10.27M
|
13.50M
|
15.96M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1,433.10
est: -88.20 (-1,524.8%)
|
-3.00
est: -3.25 (+7.7%)
|
-4.04
est: -3.91 (-3.4%)
|
-3.78
-3.92 – -3.63
+3.3% YoY
|
-2.17
-3.80 – -0.53
+42.6% YoY
|
2.61
-0.41 – 5.62
+220.0% YoY
|
4.15
4.15 – 4.15
+59.1% YoY
|
6.83
6.83 – 6.83
+64.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-16.47M
OE per share TTM
-2.17
Owner's Yield
-34.11%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
24,810.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
67
Total invested
12.95M
Insider transactions (90d)
0
Beneficial owners (>5%)
16
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 9.67M | 7.70% | — | 9.52M | 9.67M | — | HC | Delaware | 2024-11-08 | ↗ |
| 2 | CVI Investments, Inc. | 7.76M | 5.80% | — | 7.76M | — | 7.76M | CO | — | 2022-02-14 | ↗ |
| 3 | The Vanguard Group - 23-1945930 | 6.97M | 5.51% | — | — | 6.84M | 134.0K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 4 | Heights Capital Management, Inc. | 3.80M | 5.30% | — | — | — | 3.80M | CO | Cayman Islands | 2021-01-15 | ↗ |
| 5 | Intracoastal Capital LLC | 3.75M | 4.99% | — | 3.75M | — | 3.75M | OO | United States of America | 2021-01-15 | ↗ |
| 6 | L1 Capital Global Opportunities Master Fund, Ltd. | 2.30M | 9.01% | 23.00M | — | 2.30M | — | FI | Cayman Islands | 2017-11-03 | ↗ |
| 7 | Daniel B. Asher | 2.25M | 4.90% | — | 2.25M | — | 2.25M | HC, IN | United States of America | 2020-12-28 | ↗ |
| 8 | Mitchell P. Kopin | 2.25M | 4.90% | — | 2.25M | — | 2.25M | HC, IN | United States of America | 2020-12-28 | ↗ |
| 9 | CVI Investments, Inc. | 2.13M | 8.50% | — | 2.13M | — | 2.13M | CO | Delaware | 2020-12-18 | ↗ |
| 10 | Capital Management, Inc. | 2.13M | 8.50% | — | 2.13M | — | 2.13M | CO | Delaware | 2020-12-18 | ↗ |
| 11 | Empery Asset Management, LP | 1.31M | 1.03% | — | 1.31M | — | — | PN | United States | 2022-01-13 | ↗ |
| 12 | Martin D. Hoe | 1.31M | 1.03% | — | 1.31M | — | — | IN | United States | 2022-01-13 | ↗ |
| 13 | Ryan M. Lane | 1.31M | 1.03% | — | 1.31M | — | — | IN | United States | 2022-01-13 | ↗ |
| 14 | Iroquois Capital Management L.L.C. | 118.1K | 0.37% | — | 118.1K | — | 118.1K | OO | Delaware | 2018-02-14 | ↗ |
| 15 | Kimberly Page | 118.1K | 0.37% | — | 118.1K | — | 118.1K | IN | United States of America | 2018-02-14 | ↗ |
| 16 | Richard Abbe | 118.1K | 0.37% | — | 118.1K | — | 118.1K | IN | United States of America | 2018-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
67
-4 vs prev Q
New positions
13
Closed positions
15
Increased
32
Reduced
9
Put/Call ratio
0.56
Calls held
126.3K
Puts held
70.3K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | GREENBERG FINANCIAL GROUP | 18.2K +18.2K (+100.0%) | 10.75M +10.7M (+100.0%) | 0.01% +0.014 pp | 0.00% +0.004 pp | USD8.85 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 6.15M +69.0K (+1.1%) | 3.63M -1.6M (-31.2%) | 4.76% +0.053 pp | 0.00% +0.000 pp | USD3.35 +164.2% | 31 qtrs — |
| 3 | AMERIPRISE FINANCIAL INC | 3.79M +839.6K (+28.4%) | 2.24M -322.2K (-12.6%) | 2.93% +0.650 pp | 0.00% 0.000 pp | USD0.83 +966.3% | 3 qtrs — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 2.06M +514.2K (+33.2%) | 1.22M -125.6K (-9.4%) | 1.60% +0.398 pp | 0.00% +0.000 pp | USD1.15 +669.6% | 17 qtrs — |
| 5 | BLACKROCK, INC. | 2.00M +— (+0.0%) | 1.18M -553.3K (-31.9%) | 1.55% +0.000 pp | 0.00% +0.000 pp | USD1.51 +486.1% | 6 qtrs — |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.37M +9.6K (+0.7%) | 809.6K -371.8K (-31.5%) | 1.06% +0.007 pp | 0.00% +0.000 pp | USD2.64 +235.2% | 31 qtrs — |
| 7 | MILLENNIUM MANAGEMENT LLC | 1.24M -425.8K (-25.5%) | 733.3K -713.4K (-49.3%) | 0.96% -0.330 pp | 0.00% 0.000 pp | USD0.83 +966.3% | 19 qtrs — |
| 8 | JACOBS LEVY EQUITY MANAGEMENT, INC | 1.05M +1.0M (+100.0%) | 618.5K +618.5K (+100.0%) | 0.81% +0.812 pp | 0.00% +0.002 pp | USD8.85 +0.0% | 1 qtrs NEW |
| 9 | STATE STREET CORP | 596.5K +142.0K (+31.2%) | 351.9K -42.1K (-10.7%) | 0.46% +0.110 pp | 0.00% +0.000 pp | USD2.42 +265.7% | 19 qtrs — |
| 10 | UBS GROUP AG | 390.0K +129.3K (+49.6%) | 230.1K +4.1K (+1.8%) | 0.30% +0.100 pp | 0.00% +0.000 pp | USD0.97 +812.4% | 10 qtrs — |
| 11 | NORTHERN TRUST CORP | 288.4K +25.0K (+9.5%) | 170.2K -58.2K (-25.5%) | 0.22% +0.019 pp | 0.00% +0.000 pp | USD2.33 +279.8% | 26 qtrs — |
| 12 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 266.0K +17.4K (+7.0%) | 156.9K -58.6K (-27.2%) | 0.21% +0.014 pp | 0.00% 0.000 pp | USD1.01 +776.2% | 10 qtrs — |
| 13 | GRAHAM CAPITAL MANAGEMENT, L.P. | 211.4K +45.9K (+27.8%) | 124.7K -18.7K (-13.1%) | 0.16% +0.036 pp | 0.00% +0.001 pp | USD0.87 +917.2% | 2 qtrs — |
| 14 | XTX TOPCO LTD | 169.3K +144.4K (+581.2%) | 99.9K +78.3K (+363.5%) | 0.13% +0.112 pp | 0.00% +0.002 pp | USD0.85 +941.2% | 11 qtrs — |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 80.0K +— (+0.0%) | 47.2K -22.2K (-31.9%) | 0.06% +0.000 pp | 0.00% +0.000 pp | USD1.45 +510.3% | 20 qtrs — |
| 16 | ACADIAN ASSET MANAGEMENT LLC | 79.4K -17.9K (-18.4%) | 46.0K -36.0K (-43.9%) | 0.06% -0.014 pp | 0.00% 0.000 pp | USD0.87 +917.2% | 2 qtrs — |
| 17 | QUBE RESEARCH & TECHNOLOGIES LTD | 72.8K -65.8K (-47.5%) | 43.0K -77.3K (-64.3%) | 0.06% -0.051 pp | 0.00% 0.000 pp | USD1.07 +727.1% | 10 qtrs — |
| 18 | BANK OF AMERICA CORP /DE/ | 67.7K -87.5K (-56.4%) | 39.9K -94.6K (-70.3%) | 0.05% -0.068 pp | 0.00% +0.000 pp | USD1.12 +690.2% | 13 qtrs — |
| 19 | MORGAN STANLEY | 61.5K -50.8K (-45.3%) | 36.3K -61.1K (-62.7%) | 0.05% -0.039 pp | 0.00% +0.000 pp | USD2.04 +333.8% | 22 qtrs — |
| 20 | POINT72 ASSET MANAGEMENT, L.P. | 48.1K +48.1K (+100.0%) | 28.4K +28.4K (+100.0%) | 0.04% +0.037 pp | 0.00% +0.000 pp | USD8.85 +0.0% | 1 qtrs NEW |
| 21 | WILEY BROS.-AINTREE CAPITAL, LLC | 43.0K +43.0K (+100.0%) | 25.4K +25.4K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.000 pp | USD8.85 +0.0% | 1 qtrs NEW |
| 22 | JANE STREET GROUP, LLC | 40.5K +40.5K (+100.0%) | 23.9K +23.9K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.000 pp | USD8.85 +0.0% | 1 qtrs NEW |
| 23 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 38.5K +1.4K (+3.8%) | 22.7K -9.6K (-29.6%) | 0.03% +0.001 pp | 0.00% +0.000 pp | USD1.54 +474.7% | 21 qtrs — |
| 24 | JPMORGAN CHASE & CO | 38.1K -148.0 (-0.4%) | 22.5K -10.7K (-32.2%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD0.89 +894.4% | 11 qtrs — |
| 25 | CITADEL ADVISORS LLC | 31.8K -1.9K (-5.6%) | 18.8K -10.5K (-35.8%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD1.42 +523.2% | 23 qtrs — |
| 26 | REGIONS FINANCIAL CORP | 30.0K +— (+0.0%) | 17.7K -8.3K (-31.9%) | 0.02% +0.000 pp | 0.00% 0.000 pp | USD0.88 +905.7% | 9 qtrs — |
| 27 | LPL FINANCIAL LLC | 29.5K +913.0 (+3.2%) | 17.4K -7.4K (-29.8%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD1.22 +625.4% | 11 qtrs — |
| 28 | R SQUARED LTD | 28.1K +28.1K (+100.0%) | 16.6K +16.6K (+100.0%) | 0.02% +0.022 pp | 0.01% +0.008 pp | USD8.85 +0.0% | 1 qtrs NEW |
| 29 | TWO SIGMA SECURITIES, LLC | 24.5K +24.5K (+100.0%) | 14.5K +14.5K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.002 pp | USD8.85 +0.0% | 15 qtrs — |
| 30 | SIGMA PLANNING CORP | 24.0K +— (+0.0%) | 14.2K -6.6K (-31.9%) | 0.02% +0.000 pp | 0.00% 0.000 pp | USD0.87 +917.2% | 2 qtrs — |
| 31 | TWO SIGMA INVESTMENTS, LP | 23.5K +23.5K (+100.0%) | 13.8K +13.8K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.000 pp | USD8.85 +0.0% | 1 qtrs NEW |
| 32 | PFG INVESTMENTS, LLC | 21.8K +500.0 (+2.4%) | 12.8K -5.6K (-30.3%) | 0.02% +0.000 pp | 0.00% 0.000 pp | USD1.59 +456.6% | 8 qtrs — |
| 33 | LVM CAPITAL MANAGEMENT LTD/MI | 21.0K +— (+0.0%) | 12.0K -6.0K (-33.3%) | 0.02% +0.000 pp | 0.00% -0.001 pp | USD1.26 +602.4% | 11 qtrs — |
| 34 | STONEX GROUP INC. | 19.9K +19.9K (+100.0%) | 11.7K +11.7K (+100.0%) | 0.02% +0.015 pp | 0.00% +0.001 pp | USD8.85 +0.0% | 1 qtrs NEW |
| 35 | TWO SIGMA ADVISERS, LP | 18.3K +18.3K (+100.0%) | 10.8K +10.8K (+100.0%) | 0.01% +0.014 pp | 0.00% +0.000 pp | USD8.85 +0.0% | 22 qtrs — |
| 36 | DNB ASSET MANAGEMENT AS | 15.6K +— (+0.0%) | 9.2K -4.3K (-31.9%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.51 +486.1% | 6 qtrs — |
| 37 | BAADER BANK AKTIENGESELLSCHAFT | 21.4K +21.4K (+100.0%) | 7.8K +7.8K (+100.0%) | 0.02% +0.017 pp | 0.00% +0.001 pp | USD8.85 +0.0% | 3 qtrs — |
| 38 | RAYMOND JAMES FINANCIAL INC | 11.3K +508.0 (+4.7%) | 6.7K -2.7K (-28.8%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD0.94 +841.5% | 5 qtrs — |
| 39 | BANK OF NEW YORK MELLON CORP | 11.1K +— (+0.0%) | 6.6K -3.1K (-31.9%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.33 +565.4% | 20 qtrs — |
| 40 | J. L. BAINBRIDGE & CO., INC. | 11.1K +— (+0.0%) | 6.6K -3.1K (-32.0%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD6.07 +45.8% | 19 qtrs — |
| 41 | FOCUS FINANCIAL NETWORK, INC. | 10.4K +200.0 (+2.0%) | 6.1K -2.7K (-30.6%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD0.67 +1,220.9% | 4 qtrs — |
| 42 | JANNEY MONTGOMERY SCOTT LLC | 10.0K +— (+0.0%) | 6.0K -3.0K (-33.3%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.20 +637.5% | 7 qtrs — |
| 43 | ADVISOR GROUP HOLDINGS, INC. | 8.8K +— (+0.0%) | 5.2K -2.1K (-29.1%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD2.15 +311.6% | 22 qtrs — |
| 44 | FMR LLC | 7.4K +— (+0.0%) | 4.3K -2.0K (-31.9%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD0.97 +812.4% | 16 qtrs — |
| 45 | GROUP ONE TRADING, L.P. | 6.7K +6.7K (+100.0%) | 3.9K +3.9K (+100.0%) | 0.01% +0.005 pp | 0.00% +0.000 pp | USD8.85 +0.0% | 14 qtrs — |
| 46 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 5.0K +— (+0.0%) | 3.0K -1.4K (-31.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.86 +929.1% | 2 qtrs — |
| 47 | NEWEDGE ADVISORS, LLC | 5.0K +— (+0.0%) | 3.0K -1.4K (-31.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.20 +637.5% | 7 qtrs — |
| 48 | TOWER RESEARCH CAPITAL LLC (TRC) | 4.0K +1.5K (+58.9%) | 2.4K +178.0 (+8.2%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.08 +719.4% | 19 qtrs — |
| 49 | HUNTINGTON NATIONAL BANK | 3.0K +— (+0.0%) | 1.8K -831.0 (-31.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.87 +917.2% | 2 qtrs — |
| 50 | ROYAL BANK OF CANADA | 943.00 +198.0 (+26.6%) | 1.0K +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.15 +669.6% | 7 qtrs — |
| 51 | HARBOUR INVESTMENTS, INC. | 1.7K -55.0 (-3.2%) | 977.00 -506.0 (-34.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.09 +711.9% | 15 qtrs — |
| 52 | SBI SECURITIES CO., LTD. | 1.6K -1.0 (-0.1%) | 923.00 -435.0 (-32.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.94 +841.5% | 5 qtrs — |
| 53 | TD WATERHOUSE CANADA INC. | 1.6K +— (+0.0%) | 910.00 -497.0 (-35.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.55 +471.0% | 17 qtrs — |
| 54 | BNP PARIBAS ARBITRAGE, SNC | 1.5K +7.0 (+0.5%) | 883.00 -409.0 (-31.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.61 +449.7% | 19 qtrs — |
| 55 | OPTIVER HOLDING B.V. | 838.00 +838.0 (+100.0%) | 494.00 +494.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD8.84 +0.1% | 1 qtrs NEW |
| 56 | ALLWORTH FINANCIAL LP | 702.00 +— (+0.0%) | 415.00 -194.0 (-31.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.09 +323.4% | 20 qtrs — |
| 57 | JONES FINANCIAL COMPANIES LLLP | 700.00 +— (+0.0%) | 413.00 -188.0 (-31.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.66 +1,240.9% | 4 qtrs — |
| 58 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 500.00 +500.0 (+100.0%) | 295.00 +295.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.85 +0.0% | 1 qtrs NEW |
| 59 | NISA INVESTMENT ADVISORS, LLC | 350.00 +— (+0.0%) | 207.00 -96.0 (-31.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.73 +1,112.3% | 6 qtrs — |
| 60 | NBC SECURITIES, INC. | 150.00 +— (+0.0%) | 88.00 -42.0 (-32.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.80 +1,006.3% | 2 qtrs — |
| 61 | WELLS FARGO & COMPANY/MN | 83.00 +— (+0.0%) | 49.00 -23.0 (-31.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.08 +719.4% | 20 qtrs — |
| 62 | CLEARSTEAD ADVISORS, LLC | 70.00 +— (+0.0%) | 42.00 -19.0 (-31.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.07 +727.1% | 11 qtrs — |
| 63 | SRS CAPITAL ADVISORS, INC. | 42.00 +— (+0.0%) | 25.00 -11.0 (-30.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.71 +1,146.5% | 2 qtrs — |
| 64 | NORTHROCK PARTNERS, LLC | — -16.8K (-100.0%) | — -14.5K (-100.0%) | 0.00% -0.013 pp | 0.00% 0.000 pp | USD— | 7 qtrs SOLD |
| 65 | GSA CAPITAL PARTNERS LLP | — -310.8K (-100.0%) | — -269.0K (-100.0%) | 0.00% -0.241 pp | 0.00% -0.022 pp | USD— | 3 qtrs SOLD |
| 66 | TRUE WEALTH DESIGN, LLC | — -29.0 (-100.0%) | — -26.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 67 | GALLAGHER CAPITAL ADVISORS, LLC | — -31.6K (-100.0%) | — -27.5K (-100.0%) | 0.00% -0.024 pp | 0.00% -0.016 pp | USD— | 5 qtrs SOLD |
| 68 | EVERSOURCE WEALTH ADVISORS, LLC | — -2.0 (-100.0%) | — -2.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 69 | COMMONWEALTH EQUITY SERVICES, LLC | — -46.0K (-100.0%) | — -40.0K (-100.0%) | 0.00% -0.036 pp | 0.00% 0.000 pp | USD— | 8 qtrs SOLD |
| 70 | HRT FINANCIAL LP | — -16.9K (-100.0%) | — -14.0K (-100.0%) | 0.00% -0.013 pp | 0.00% 0.000 pp | USD— | 5 qtrs SOLD |
| 71 | MARSHALL WACE, LLP | — -85.1K (-100.0%) | — -74.0K (-100.0%) | 0.00% -0.066 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 72 | VICTORY CAPITAL MANAGEMENT INC | — -14.9K (-100.0%) | — -12.9K (-100.0%) | 0.00% -0.012 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
| 73 | JAIN GLOBAL LLC | — -16.7K (-100.0%) | — -14.5K (-100.0%) | 0.00% -0.013 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 74 | BARCLAYS PLC | — -167.7K (-100.0%) | — -254.9K (-100.0%) | 0.00% -0.130 pp | 0.00% 0.000 pp | USD— | 7 qtrs SOLD |
| 75 | SQUAREPOINT OPS LLC | — -253.3K (-100.0%) | — -219.6K (-100.0%) | 0.00% -0.196 pp | 0.00% 0.000 pp | USD— | 9 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.00% | 69.2K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 506.4K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 2.8K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 7.8K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 575.82 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.33M | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.9K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.6K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 641.90 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 70.73 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
1.28M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+1,275,203
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-27 | QUAY STEVEN C | Director / Officer | A-Award | A | Common Stock | 65,000 | 0.00 | — | 88,038 | D | ↗ |
| 2026-03-26 | Daniel Mark James | Officer | A-Award | A | Common Stock | 63,000 | 0.00 | — | 63,000 | D | ↗ |
| 2026-01-20 | QUAY STEVEN C | Director / Officer | A-Award | A | Common Stock | 331,674 | 0.00 | — | 345,572 | D | ↗ |
| 2025-10-14 | Daniel Mark James | Officer | A-Award | A | Stock Option (right to buy) | 578,000 | 1.03 | 595.3K | 578,000 | D | ↗ |
| 2025-05-21 | QUAY STEVEN C | Director / Officer | P-Purchase | A | Common Stock | 11,239 | 0.88 | 9.9K | 13,898 | D | ↗ |
| 2025-05-15 | Steinhart Richard I | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.99 | 123.8K | 125,000 | D | ↗ |
| 2025-05-15 | Remmel H. Lawrence | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.99 | 123.8K | 125,000 | D | ↗ |
| 2025-05-15 | Rees Heather | Officer | A-Award | A | Stock Option (right to buy) | 543,785 | 0.99 | 538.3K | 543,785 | D | ↗ |
| 2025-05-15 | QUAY STEVEN C | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,366,062 | 0.99 | 1.35M | 1,366,062 | D | ↗ |
| 2025-05-15 | Galli Stephen J | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.99 | 123.8K | 125,000 | D | ↗ |
| 2025-05-15 | Finn Jonathan | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.99 | 123.8K | 125,000 | D | ↗ |
| 2025-05-15 | Cigler Tessa | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.99 | 123.8K | 125,000 | D | ↗ |
| 2025-05-15 | Chen Shu-Chih | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.99 | 123.8K | 125,000 | D | ↗ |
| 2025-03-26 | Remmel H. Lawrence | Director | P-Purchase | A | Common Stock | 10,000 | 0.70 | 7.0K | 10,257 | D | ↗ |
| 2024-06-27 | Steinhart Richard I | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 1.05 | 131.3K | 125,000 | — | ↗ |
| 2024-06-27 | Remmel H. Lawrence | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 1.05 | 131.3K | 125,000 | — | ↗ |
| 2024-06-27 | Rees Heather | Officer | A-Award | A | Stock Option (right to buy) | 577,700 | 1.05 | 606.6K | 577,700 | — | ↗ |
| 2024-06-27 | QUAY STEVEN C | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,795,100 | 1.05 | 1.88M | 1,795,100 | — | ↗ |
| 2024-06-27 | Galli Stephen J | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 1.05 | 131.3K | 125,000 | — | ↗ |
| 2024-06-27 | Finn Jonathan | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 1.05 | 131.3K | 125,000 | — | ↗ |
| 2024-06-27 | Cigler Tessa | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 1.05 | 131.3K | 125,000 | — | ↗ |
| 2024-06-27 | Chen Shu-Chih | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 1.05 | 131.3K | 125,000 | — | ↗ |
| 2024-04-10 | Finn Jonathan | Director | P-Purchase | A | Common Stock | 25,000 | 1.77 | 44.3K | 25,000 | — | ↗ |
| 2024-03-09 | Cigler Tessa | Director | A-Award | A | Stock Option (right to buy) | 20,834 | 1.09 | 22.7K | 20,834 | — | ↗ |
| 2023-11-15 | WEAVER GREGORY L | Director / Officer | S-Sale | D | Common Stock | 50,000 | 0.65 | 32.5K | 55 | — | ↗ |
| 2023-11-15 | Finn Jonathan | Director | A-Award | A | Stock Option (right to buy) | 62,500 | 0.65 | 40.6K | 62,500 | — | ↗ |
| 2023-11-08 | Finn Jonathan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-10-06 | Rees Heather | Officer | — | D | Stock Option (Right to Buy) | 226,000 | 0.92 | 207.9K | 0 | — | ↗ |
| 2023-06-20 | WEAVER GREGORY L | Director / Officer | P-Purchase | A | Common Stock | 50,000 | 0.97 | 48.5K | 50,055 | — | ↗ |
| 2023-06-01 | WEAVER GREGORY L | Director / Officer | A-Award | A | Stock Option (right to buy) | 2,600,000 | 0.92 | 2.39M | 2,600,000 | — | ↗ |
| 2023-05-04 | WEAVER GREGORY L | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.66 | 82.8K | 125,000 | — | ↗ |
| 2023-05-04 | Steinhart Richard I | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.66 | 82.8K | 125,000 | — | ↗ |
| 2023-05-04 | Remmel H. Lawrence | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.66 | 82.8K | 125,000 | — | ↗ |
| 2023-05-04 | Galli Stephen J | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.66 | 82.8K | 125,000 | — | ↗ |
| 2023-05-04 | Chen Shu-Chih | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.66 | 82.8K | 125,000 | — | ↗ |
| 2023-03-02 | QUAY STEVEN C | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,873,100 | 0.72 | 1.35M | 1,873,100 | — | ↗ |
| 2023-03-02 | Guse Kyle | Officer | A-Award | A | Stock Option (right to buy) | 557,900 | 0.72 | 401.7K | 557,900 | — | ↗ |
| 2022-05-13 | WEAVER GREGORY L | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.93 | 46.5K | 50,000 | — | ↗ |
| 2022-05-13 | Steinhart Richard I | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.00 | — | 500,000 | — | ↗ |
| 2022-05-13 | Remmel H. Lawrence | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-05-13 | Galli Stephen J | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-05-13 | Chen Shu-Chih | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.93 | 46.5K | 50,000 | — | ↗ |
| 2022-02-24 | QUAY STEVEN C | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,900,000 | 1.25 | 2.38M | 1,900,000 | — | ↗ |
| 2022-02-24 | Guse Kyle | Officer | A-Award | A | Stock Option (right to buy) | 746,667 | 1.25 | 933.3K | 746,667 | — | ↗ |
| 2021-07-02 | WEAVER GREGORY L | Director | M-Exempt | A | Common Stock | 4,581 | 5.64 | 25.8K | 4,581 | — | ↗ |
| 2021-05-14 | WEAVER GREGORY L | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 2.90 | 145.0K | 50,000 | — | ↗ |
| 2021-05-14 | Steinhart Richard I | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 2.90 | 145.0K | 50,000 | — | ↗ |
| 2021-05-14 | Remmel H. Lawrence | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 2.90 | 145.0K | 50,000 | — | ↗ |
| 2021-05-14 | QUAY STEVEN C | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,900,000 | 2.90 | 5.51M | 1,900,000 | — | ↗ |
| 2021-05-14 | Guse Kyle | Officer | A-Award | A | Stock Option (right to buy) | 850,000 | 2.90 | 2.47M | 850,000 | — | ↗ |
| 2021-05-14 | Galli Stephen J | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 2.90 | 145.0K | 50,000 | — | ↗ |
| 2021-05-14 | Chen Shu-Chih | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 2.90 | 145.0K | 50,000 | — | ↗ |
| 2020-05-15 | WEAVER GREGORY L | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 1.70 | 119.0K | 70,000 | — | ↗ |
| 2020-05-15 | Steinhart Richard I | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 1.70 | 76.5K | 45,000 | — | ↗ |
| 2020-05-15 | Remmel H. Lawrence | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 1.70 | 76.5K | 45,000 | — | ↗ |
| 2020-05-15 | Galli Stephen J | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 1.70 | 76.5K | 45,000 | — | ↗ |
| 2020-05-15 | Chen Shu-Chih | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 1.70 | 76.5K | 45,000 | — | ↗ |
| 2020-04-09 | QUAY STEVEN C | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,305,000 | 1.48 | 1.93M | 1,305,000 | — | ↗ |
| 2020-04-09 | Guse Kyle | Officer | A-Award | A | Stock Option (Right to Buy) | 395,000 | 1.48 | 584.6K | 395,000 | — | ↗ |
| 2019-05-17 | WEAVER GREGORY L | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 2.52 | 113.4K | 45,000 | — | ↗ |
| 2019-05-17 | Steinhart Richard I | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 2.52 | 113.4K | 45,000 | — | ↗ |
| 2019-05-17 | Remmel H. Lawrence | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 2.52 | 113.4K | 45,000 | — | ↗ |
| 2019-05-17 | Galli Stephen J | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 2.52 | 113.4K | 45,000 | — | ↗ |
| 2019-05-17 | Chen Shu-Chih | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 2.52 | 113.4K | 45,000 | — | ↗ |
| 2019-01-13 | QUAY STEVEN C | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 2,300,000 | 1.36 | 3.13M | 2,300,000 | — | ↗ |
| 2019-01-13 | Guse Kyle | Officer | A-Award | A | Stock Option (Right to Buy) | 800,000 | 1.36 | 1.09M | 800,000 | — | ↗ |
| 2018-06-27 | WEAVER GREGORY L | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 2.38 | 107.1K | 45,000 | — | ↗ |
| 2018-06-27 | Steinhart Richard I | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 2.38 | 107.1K | 45,000 | — | ↗ |
| 2018-06-27 | Remmel H. Lawrence | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 2.38 | 107.1K | 45,000 | — | ↗ |
| 2018-06-27 | QUAY STEVEN C | Director / Officer | A-Award | A | Stock Option (right to buy) | 2,300,000 | 2.38 | 5.47M | 2,300,000 | — | ↗ |
| 2018-06-27 | Guse Kyle | Officer | A-Award | A | Stock Option (right to buy) | 700,000 | 2.38 | 1.67M | 700,000 | — | ↗ |
| 2018-06-27 | Galli Stephen J | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 2.38 | 107.1K | 45,000 | — | ↗ |
| 2018-06-27 | Chen Shu-Chih | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 2.38 | 107.1K | 45,000 | — | ↗ |
| 2018-05-30 | QUAY STEVEN C | Director / Officer | P-Purchase | A | Warrants | 2,272 | 4.05 | 9.2K | 2,272 | — | ↗ |
| 2018-05-30 | Guse Kyle | Officer | P-Purchase | A | Warrants | 2,272 | 4.05 | 9.2K | 2,272 | — | ↗ |
| 2018-05-30 | Chen Shu-Chih | Director | P-Purchase | A | Series B Convertible Preferred Stock | 8 | 3.52 | 28.16 | 8 | — | ↗ |
| 2017-11-15 | Guse Kyle | Officer | P-Purchase | A | Common Stock | 1,400 | 0.34 | 471.10 | 10,000 | — | ↗ |
| 2017-05-24 | WEAVER GREGORY L | Director | A-Award | A | Stock Option (right to buy) | 54,949 | 0.47 | 25.8K | 69,917 | — | ↗ |
| 2017-05-24 | Steinhart Richard I | Director | A-Award | A | Stock Option (right to buy) | 49,531 | 0.47 | 23.3K | 59,062 | — | ↗ |
| 2017-05-24 | Remmel H. Lawrence | Director | A-Award | A | Stock Option (right to buy) | 57,685 | 0.47 | 27.1K | 75,369 | — | ↗ |
| 2017-05-24 | QUAY STEVEN C | Director / Officer | A-Award | A | Stock Option (right to buy) | 575,893 | 0.47 | 270.7K | 651,785 | — | ↗ |
| 2017-05-24 | Guse Kyle | Officer | A-Award | A | Stock Option (right to buy) | 495,333 | 0.47 | 232.8K | 640,667 | — | ↗ |
| 2017-05-24 | Galli Stephen J | Director | A-Award | A | Stock Option (right to buy) | 64,132 | 0.47 | 30.1K | 88,263 | — | ↗ |
| 2017-05-24 | Chen Shu-Chih | Director | A-Award | A | Stock Option (right to buy) | 60,202 | 0.47 | 28.3K | 80,404 | — | ↗ |
| 2017-04-17 | Remmel H. Lawrence | Director | P-Purchase | A | Common Stock | 2,500 | 0.63 | 1.6K | 3,126 | — | ↗ |
| 2016-05-18 | WEAVER GREGORY L | Director | A-Award | A | Stock Option (right to buy) | 112,190 | 0.26 | 29.5K | 112,190 | — | ↗ |
| 2016-05-18 | Steinhart Richard I | Director | A-Award | A | Stock Option (right to buy) | 71,484 | 0.26 | 18.8K | 71,484 | — | ↗ |
| 2016-05-18 | Remmel H. Lawrence | Director | A-Award | A | Stock Option (right to buy) | 132,634 | 0.26 | 34.9K | 132,634 | — | ↗ |
| 2016-05-18 | QUAY STEVEN C | Director / Officer / 10% Owner | A-Award | A | Common Stock (right to buy) | 569,194 | 0.26 | 149.7K | 569,194 | — | ↗ |
| 2016-05-18 | Guse Kyle | Officer | A-Award | A | Stock Option (right to buy) | 1,090,000 | 0.26 | 286.7K | 1,090,000 | — | ↗ |
| 2016-05-18 | Galli Stephen J | Director | A-Award | A | Stock Option (right to buy) | 180,987 | 0.26 | 47.6K | 180,987 | — | ↗ |
| 2016-05-18 | Chen Shu-Chih | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 151,516 | 0.26 | 39.8K | 151,516 | — | ↗ |
| 2016-04-01 | Remmel H. Lawrence | Director | P-Purchase | A | Common Stock | 1,500 | 0.33 | 495.00 | 10,900 | — | ↗ |
| 2016-03-09 | QUAY STEVEN C | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 15,000 | 0.37 | 5.6K | 4,826,858 | — | ↗ |
| 2016-03-09 | Chen Shu-Chih | Director / 10% Owner | P-Purchase | A | Common Stock | 15,000 | 0.37 | 5.6K | 4,348,315 | — | ↗ |
| 2016-02-16 | QUAY STEVEN C | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 15,000 | 0.53 | 8.0K | 4,811,858 | — | ↗ |
| 2016-02-16 | Chen Shu-Chih | Director / 10% Owner | P-Purchase | A | Common Stock | 15,000 | 0.53 | 8.0K | 4,333,315 | — | ↗ |
| 2016-01-19 | QUAY STEVEN C | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 50,000 | 0.20 | 10.0K | 4,796,858 | — | ↗ |
| 2016-01-19 | Chen Shu-Chih | Director / 10% Owner | P-Purchase | A | Common Stock | 50,000 | 0.20 | 10.0K | 4,318,315 | — | ↗ |
| 2015-09-01 | Youmans Scott | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 0.76 | 38.0K | 286,217 | — | ↗ |
| 2015-06-12 | Remmel H. Lawrence | Director | P-Purchase | A | Common Stock | 5,400 | 1.30 | 7.0K | 9,400 | — | ↗ |
| 2015-05-12 | WEAVER GREGORY L | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 1.37 | 54.8K | 40,000 | — | ↗ |
| 2015-05-12 | Steinhart Richard I | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 1.37 | 54.8K | 40,000 | — | ↗ |
| 2015-05-12 | Remmel H. Lawrence | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 1.37 | 54.8K | 40,000 | — | ↗ |
| 2015-05-12 | Galli Stephen J | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 1.37 | 54.8K | 40,000 | — | ↗ |
| 2015-03-16 | Sawyer John E | Officer | A-Award | A | Stock Options | 59,265 | 1.88 | 111.4K | 59,265 | — | ↗ |
| 2015-03-16 | QUAY STEVEN C | Director / Officer / 10% Owner | A-Award | A | Stock Options | 275,000 | 1.88 | 517.0K | 275,000 | — | ↗ |
| 2015-03-16 | Guse Kyle | Officer | A-Award | A | Stock Options | 190,000 | 1.88 | 357.2K | 190,000 | — | ↗ |
| 2015-03-16 | Destro Christopher S. | Officer | A-Award | A | Stock Options | 54,625 | 1.88 | 102.7K | 54,625 | — | ↗ |
| 2014-06-02 | Sawyer John E | Officer | — | D | Stock Option (right to buy) | 200,000 | 1.41 | 282.0K | 0 | — | ↗ |
| 2014-05-06 | WEAVER GREGORY L | Director | D-Return | D | Common Stock | 24,510 | 0.00 | — | 0 | — | ↗ |
| 2014-05-06 | Steinhart Richard I | Director | D-Return | D | Common Stock | 22,728 | 0.00 | — | 0 | — | ↗ |
| 2014-05-06 | Remmel H. Lawrence | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.22 | 18.3K | 15,000 | — | ↗ |
| 2014-05-06 | QUAY STEVEN C | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 250,000 | 1.22 | 305.0K | 250,000 | — | ↗ |
| 2014-05-06 | Guse Kyle | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 1.22 | 244.0K | 200,000 | — | ↗ |
| 2014-05-06 | Galli Stephen J | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.22 | 18.3K | 15,000 | — | ↗ |
| 2014-05-06 | Destro Christopher S. | Officer | — | I | Common Stock | 0 | 0.00 | — | 100 | — | ↗ |
| 2014-05-06 | Chen Shu-Chih | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 125,000 | 1.22 | 152.5K | 125,000 | — | ↗ |
| 2014-05-06 | Carbonaro Peter J. | Officer | — | D | Stock Option (right to buy) | 45,000 | 1.22 | 54.9K | 0 | — | ↗ |
| 2014-04-01 | Chen Ben R | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-03-01 | Steinhart Richard I | Director | A-Award | A | Common Stock | 22,728 | 0.00 | — | 22,728 | — | ↗ |
| 2014-01-08 | Guse Kyle | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 2.20 | 308.0K | 140,000 | — | ↗ |
| 2013-12-31 | QUAY STEVEN C | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 4,268,315 | — | ↗ |
| 2013-12-31 | Chen Shu-Chih | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 4,268,315 | — | ↗ |
| 2013-11-21 | WEAVER GREGORY L | Director | P-Purchase | A | Common Stock | 10,000 | 2.58 | 25.8K | 34,510 | — | ↗ |
| 2013-10-10 | WEAVER GREGORY L | Director | A-Award | A | Common Stock | 24,510 | 0.00 | — | 24,510 | — | ↗ |
| 2013-10-01 | QUAY STEVEN C | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 7,265 | 5.66 | 41.1K | 4,268,315 | — | ↗ |
| 2013-10-01 | Chen Shu-Chih | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 7,265 | 5.66 | 41.1K | 4,268,315 | — | ↗ |
| 2013-06-04 | Guse Kyle | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 4.31 | 258.6K | 60,000 | — | ↗ |
| 2013-05-15 | CROSS ALEXANDER D | Director | P-Purchase | A | Common Stock | 500 | 5.49 | 2.7K | 88,866 | — | ↗ |
| 2013-05-07 | Galli Stephen J | Director | A-Award | A | Stock Option (right to buy) | 40,030 | 6.60 | 264.0K | 40,030 | — | ↗ |
| 2013-05-07 | CROSS ALEXANDER D | Director | A-Award | A | Stock Option (right to buy) | 41,243 | 6.60 | 272.0K | 41,243 | — | ↗ |
| 2013-05-07 | Barnhart John | Director | A-Award | A | Stock Option (right to buy) | 44,882 | 6.60 | 296.0K | 44,882 | — | ↗ |
| 2013-03-11 | QUAY STEVEN C | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 44,194 | 6.57 | 290.4K | 44,194 | — | ↗ |
| 2013-03-11 | Chen Shu-Chih | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 26,516 | 6.57 | 174.2K | 26,516 | — | ↗ |
| 2013-01-08 | Remmel H. Lawrence | Director | P-Purchase | A | Common Stock | 2,000 | 4.05 | 8.1K | 2,000 | — | ↗ |
| 2013-01-04 | Guse Kyle | Officer | — | D | Stock Option (right to buy) | 500,000 | 4.11 | 2.06M | 0 | — | ↗ |
| 2012-11-07 | Remmel H. Lawrence | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-11-07 | QUAY STEVEN C | Director / Officer / 10% Owner | — | D | Stock Option (Right to Buy) | 250,000 | 2.64 | 660.0K | 0 | — | ↗ |
| 2012-11-07 | Galli Stephen J | Director | — | D | Stock Option (Right to Buy) | 5,927 | 6.00 | 35.6K | 0 | — | ↗ |
| 2012-11-07 | Chen Shu-Chih | Director / Officer / 10% Owner | — | D | Stock Option (Right to Buy) | 100,000 | 2.64 | 264.0K | 0 | — | ↗ |
| 2012-11-07 | CROSS ALEXANDER D | Director | — | D | Stock Option (Right to Buy) | 5,927 | 6.00 | 35.6K | 0 | — | ↗ |
| 2012-11-07 | Benjamin Christopher | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-11-07 | Barnhart John | Director | — | I | Common Stock | 0 | 0.00 | — | 8,837 | — | ↗ |
Executive team
Top executives
Shares Outstanding
8.61M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Steven C. Quay, M.D., Ph. D. | 731.0K | — | — | 1.48M | 250.0K | 39.2K | 2.50M | 59.24% | ↗ |
| 2 | 2025 | Heather Rees, CPA (Inactive) | 482.2K | — | — | 415.9K | — | 83.6K | 981.7K | 42.37% | ↗ |
| 3 | 2025 | Mark J. Daniel | 72.5K | — | — | 456.1K | — | 7.9K | 536.5K | 85.02% | ↗ |
| 4 | 2024 | Steven C. Quay, M.D., Ph. D. | 705.9K | — | — | 1.49M | 529.4K | 38.1K | 2.76M | 53.93% | ↗ |
| 5 | 2024 | Heather Rees, CPA (inactive) | 402.5K | — | — | 489.2K | 219.9K | 38.1K | 1.15M | 42.55% | ↗ |
| 6 | 2024 | Heather Rees, CPA (Inactive) | 402.5K | — | — | 489.2K | 219.9K | 38.1K | 1.15M | 42.55% | ↗ |
| 7 | 2023 | Greg Weaver | 197.8K | 43.5K | — | 2.12M | — | 21.8K | 2.38M | 88.95% | ↗ |
| 8 | 2023 | Steven C. Quay, M.D. Ph. D. | 705.9K | — | — | 1.14M | 469.8K | 36.6K | 2.36M | 48.55% | ↗ |
| 9 | 2023 | Steven C. Quay, M.D., Ph. D. | 705.9K | — | — | 1.14M | 469.8K | 36.6K | 2.36M | 48.55% | ↗ |
| 10 | 2023 | Kyle Guse | 248.4K | — | — | 342.8K | — | 580.5K | 1.17M | 29.26% | ↗ |
| 11 | 2023 | Heather Rees, CPA (inactive) | 331.6K | — | — | 166.8K | 152.5K | 36.6K | 687.5K | 24.27% | ↗ |
| 12 | 2022 | Steven C. Quay, M.D. Ph. D. | 705.9K | — | — | 2.02M | 402.4K | 32.9K | 3.16M | 63.90% | ↗ |
| 13 | 2022 | Steven C. Quay, MD., Ph.D. | 705.9K | — | — | 2.02M | 402.4K | 32.9K | 3.16M | 63.90% | ↗ |
| 14 | 2022 | Kyle Guse | 466.7K | — | — | 788.9K | 239.4K | 32.9K | 1.53M | 51.64% | ↗ |
| 15 | 2021 | Steven C. Quay, MD., Ph.D. | 659.0K | — | — | 4.71M | 494.3K | 31.4K | 5.89M | 79.90% | ↗ |
| 16 | 2021 | Kyle Guse | 456.7K | — | — | 2.11M | 205.5K | 31.4K | 2.80M | 75.24% | ↗ |
| 17 | 2020 | Steven C. Quay, MD., Ph.D. | 600.6K | — | — | 1.99M | 330.3K | 13.6K | 2.94M | 67.83% | ↗ |
| 18 | 2020 | Kyle Guse | 421.1K | — | — | 761.3K | 189.5K | 13.6K | 1.39M | 54.95% | ↗ |
| 19 | 2019 | Steven C. Quay, MD., Ph.D. | 600.6K | — | — | 4.89M | 300.3K | 18.7K | 5.81M | 84.17% | ↗ |
| 20 | 2019 | Kyle Guse | 421.1K | — | — | 1.70M | 189.5K | 18.7K | 2.33M | 72.99% | ↗ |
| 21 | 2018 | Steven C. Quay, MD., Ph.D. | 582.0K | — | — | 1.08M | 491.0K | 18.3K | 2.17M | 49.76% | ↗ |
| 22 | 2018 | Kyle Guse | 408.0K | — | — | 329.0K | 333.6K | 18.3K | 1.09M | 30.21% | ↗ |
| 23 | 2017 | Steven C. Quay, M.D., Ph.D. President and Chief Executive Officer | 520.0K | — | — | 227.7K | 260.0K | 12.0K | 1.02M | 22.33% | ↗ |
| 24 | 2017 | Steven C. Quay, MD., Ph.D. | 520.0K | — | — | 227.7K | 260.0K | 12.0K | 1.02M | 22.33% | ↗ |
| 25 | 2017 | Kyle Guse | 364.0K | — | — | 195.9K | 163.8K | 12.0K | 735.7K | 26.63% | ↗ |
| 26 | 2017 | Kyle Guse Chief Financial Officer, General Counsel and Secretary | 364.0K | — | — | 195.9K | 163.8K | 12.0K | 735.7K | 26.63% | ↗ |
| 27 | 2016 | Steven C. Quay, M.D., Ph.D. President and Chief Executive Officer | 520.0K | — | — | 125.0K | 300.0K | 10.6K | 955.6K | 13.08% | ↗ |
| 28 | 2016 | Kyle Guse Chief Financial Officer, General Counsel and Secretary | 364.0K | — | — | 239.3K | 170.0K | 10.6K | 783.9K | 30.53% | ↗ |
| 29 | 2016 | Scott Youmans Chief Operating Officer | 34.3K | — | — | — | 104.3K | — | 138.6K | 0.00% | ↗ |
| 30 | 2015 | Steven C. Quay, M.D., Ph.D. President and Chief Executive Officer | 520.0K | — | — | 437.6K | 208.0K | 10.6K | 1.18M | 37.20% | ↗ |
| 31 | 2015 | Kyle Guse Chief Financial Officer, General Counsel and Secretary | 364.0K | — | — | 302.3K | 131.0K | 10.6K | 808.0K | 37.42% | ↗ |
| 32 | 2015 | Scott Youmans Chief Operating Officer | 239.2K | — | — | 88.9K | 80.4K | 2.9K | 411.3K | 21.61% | ↗ |
| 33 | 2015 | Christopher Destro Senior Vice President of Sales and Marketing | 103.3K | — | — | 86.9K | — | 125.5K | 315.7K | 27.53% | ↗ |
| 34 | 2015 | John Sawyer Senior Vice President of Regulatory Affairs and Quality Assurance | 150.0K | — | — | 94.3K | — | — | 244.3K | 38.60% | ↗ |
| 35 | 2015 | Shu-Chih Chen, Ph.D. | — | — | — | — | — | — | — | — | ↗ |
| 36 | 2015 | H. Lawrence Remmel, Esq. Steven C. Quay, M.D., Ph.D. Gregory L. Weaver Stephen J. Galli, M.D. Richard I. Steinhart | — | — | — | — | — | — | — | — | ↗ |
| 37 | 2014 | Steven C. Quay, M.D., Ph.D. President and Chief Executive Officer | 500.0K | — | — | 129.1K | 225.0K | 10.4K | 864.5K | 14.94% | ↗ |
| 38 | 2014 | Kyle Guse Chief Financial Officer, General Counsel and Secretary | 350.0K | — | — | 236.2K | 149.6K | 10.4K | 746.2K | 31.65% | ↗ |
| 39 | 2014 | Christopher Destro Senior Vice President of Sales and Marketing | 205.0K | — | — | 70.7K | 46.6K | 10.4K | 332.7K | 21.25% | ↗ |
| 40 | 2014 | John Sawyer Senior Vice President of Regulatory Affairs and Quality Assurance | 163.3K | — | — | 119.3K | 43.3K | — | 325.9K | 36.60% | ↗ |
| 41 | 2014 | Scott Youmans Chief Operating Officer | 67.1K | — | — | 156.6K | 31.7K | — | 255.5K | 61.31% | ↗ |
| 42 | 2014 | Richard I. Steinhart Steven C. Quay, M.D., Ph.D. Gregory L. Weaver Shu-Chih Chen, Ph.D. H. Lawrence Remmel, Esq. | — | — | — | — | — | — | — | — | ↗ |
| 43 | 2014 | Stephen J. Galli, M.D. | — | — | — | — | — | — | — | — | ↗ |
| 44 | 2012 | Steven C. Quay, M.D., Ph.D. President and Chief Executive Officer | 250.0K | 72.6K | — | — | — | — | 322.6K | 0.00% | ↗ |
| 45 | 2012 | Shu-Chih Chen, Ph.D. Chief Scientific Officer | 200.0K | 43.6K | — | — | — | — | 243.6K | 0.00% | ↗ |
| 46 | 2012 | Christopher Benjamin Chief Financial Officer | 109.3K | — | — | — | — | — | 109.3K | 0.00% | ↗ |
| 47 | 2011 | Steven C. Quay, M.D., Ph.D. President and Chief Executive Officer | 250.0K | 61.9K | — | — | — | — | 311.9K | 0.00% | ↗ |
| 48 | 2011 | Shu-Chih Chen, Ph.D. Chief Scientific Officer | 200.0K | 37.1K | — | — | — | — | 237.1K | 0.00% | ↗ |
| 49 | 2011 | Christopher Benjamin Chief Financial Officer | 39.0K | — | — | — | — | — | 39.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Steven C. Quay FCAP | Chairman, Chief Executive Officer & President | 1M | — |
| Mark Daniel | Chief Financial Officer | 349.3K | male |
| Delly Behen | Senior Vice President of Business Operations | — | female |
| Janet Rose Rea MSPH | Senior Vice President of Research & Development | — | female |
| Richard Graydon | Interim Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2017-10-25 | 2018-08-06 | Roger W. Marshall | Ks01 | Dependent | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ATOS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
